Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For you :)
What are you talking about
Doesnt take much to know the trades. Check your level 2s with the buys amd sells. Buys outweight sells. Trading 101
Crazy buys! This could go to pennies
Back in the green
Consolidating nicely. This will move up a 100%+ runner here. Well get green very soon
ARIA Treatment Facility Fully Licensed
West Palm Beach, FL, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Ethema Health Corporation (OTCPINK: GRST) (“Ethema” “GRST” or the “Company”) is pleased to announce that the audit for the full licensing of the ARIA treatment facility by the Department of Children and Family Service for Florida (“DCF”) which commenced on December 10, 2020 has resulted in the issuance of a full license for all five levels of care that ARIA provides. The issuance of the full licenses for each level of care were staggered and the full licenses for the final two levels of care were received January 12, 2021. The Company previously announced that it had expected the process to take several days and instead took just over a month. The licensing process has become far more arduous in recent months due to many new requirements by DCF and it has been in many ways a new experience for the providers and DCF. The scores that ARIA received for the various categories graded, averaged just under 99%, with no individual score under 98%. This granting of the full licenses will allow ARIA to move forward with the pursuit of in-network contracts with various insurers.
ARIA finished November and December with out-of-network gross billing of $602,200.00. The rate paid by insurers on out-of-network billings varies by insurer and under GAAP accounting rules, providers are required to report gross billings based on the date of service with a reserve or contingency for uncollectable amounts resulting in the net reported income for any period. The net reported income number is reported in the Company’s quarterly and annual filings. Initial billings for a new provider often take several months to get set up with insurers before a provider will start receiving payments. ARIA received its first payment on January 8, 2021, only 69 days after its first date of service. This is a tremendous result thanks to the great work of ARIA’s contracted third-party billing company.
The Company previously reported the restructuring of the debt due to Leonite Capital LLC (“Leonite”) whereby the bulk of the debt was converted to preferred shares in the Company and one of the Company’s subsidiaries, with the remainder written down to $150,000 (the “Remainder Portion”). Under this agreement the Company and Leonite agreed that there would not be any conversions at any time prior to October 31, 2020 and allowed thereafter. The company received conversion notices to convert the debt to shares and the shares were issued on December 31, 2020 and January 12, 2021 in full satisfaction of the Remainder Portion of the Leonite debt.
The Pay per Click advertising campaign being run by ARIA is now in full rollout and is working effectively. ARIA also continues to have great success in managing the spread of Covid-19 at the new facility and attributes that success to the use of the Covid Clear product in the treatment of the facility environment, the use of PPE and testing as often as possible. Palm Beach County has been particularly hard hit with Covid-19 cases and ARIA has managed to keep the staff and clients free from the virus to date. The use of vaccines will be highly recommended to staff and clients as they become available.
Talking about GRST to himself. Havent seen that in a while
Looking good :)
Holding strong. Cooling off the RSIs a little. Has plenty of room to go
GNBT - On January 6, 2021, Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) agreed to accept a One Hundred Thousand Dollar USD ($100,000.00) “Performance Guarantee Fee” payment to extend, for a second time, the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment from the “Joint Entity” (the “Performance Guarantee Fee Agreement”) as set forth under the Ii-Key Innovative Vaccine Development Agreement
Long term stock to hold for sure. This should be over $1
Holy buying spree! Nice pop up today. More on its way great news and deals coming up!
Niceeee movement! Back to $1 plus?
Wow this is moving. Never thought Id see the day. Well great move QBAN. Crazy buying
GNBT / NGIO - NGIO Evaluated at 500 Million!
Link: https://www.otcmarkets.com/stock/GNBT/news/Generex-Biotechnology-Announces-Investor-Conference-Call-Scheduled-for-Friday-February-5-2021-at-900-AM?id=285672
We e have completed our ex vivo human trial of COVID-19 patient samples and can confirm that the results of the T cell activation and antibody screen have enabled us to select Ii-Key-SARS-CoV-2 epitopes for our vaccine formulation. I will provide an update on these results as well as the results of our ongoing immunogenicity study that will confirm the commercial viability of our Ii-Key vaccine. In addition, I will update everyone on our progress and timing on the NuGenerex Immuno-Oncology Nasdaq listing now that our third-party valuation analysis has been completed with a value estimated at over $500 million. This third-party valuation report is the last piece of information required to enable us to set the price per share to meet the standards for the Nasdaq. I will also provide a complete corporate update including discussions of our subsidiaries”.
GNBT - On January 6, 2021, Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) agreed to accept a One Hundred Thousand Dollar USD ($100,000.00) “Performance Guarantee Fee” payment to extend, for a second time, the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment from the “Joint Entity” (the “Performance Guarantee Fee Agreement”) as set forth under the Ii-Key Innovative Vaccine Development Agreement
Still strong! Loving it
Looking strong!
Nice bid support
Charts are reversing upward. Level 2s cleared up significantly. Its ready to move soon
I think also what is important is that someone is buying up all these shares. Could be a very good move up very soon.
$GNBT News! Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine(TM)
December, 31 2020 09:00 AMGenerex Biotechnology?
Link: https://marketwirenews.com/amp/news-releases/generex-and-nugenerex-immuno-oncology-provide-update-5188960933042271.html?__twitter_impression=true
The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS)
Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical supply
Ii-Key epitopes selected that elicit both CD4+ T Helper cell (Th1) and CD8+ responses that are necessary for long-term immune memory
Ii-Key epitopes elicited no Th2 T cell responses that have been linked to antibody dependent enhancement of disease and cytokine storm
Ii-Key epitopes have been used to purify Anti-SARS-CoV-2 antibodies from convalescent COVID-19 patient serum
Neutralizing antibodies purified with Ii-Key epitopes have potential as a therapeutic treatment for COVID-19
Addressing emergence of mutant coronavirus strains
Exploring new opportunities to utilize Ii-Key-SARS-CoV-2 vaccines as a targeted universal booster designed to alleviate the immune related side effects reported with the current RNA vaccines
MIRAMAR, Fla., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ;) today announced that its majority owned public entity, NuGenerex Immuno-Oncology, Inc. (NGIO), has filed for and expects to receive a trademark for The Complete Vaccine™. A complete vaccine is designed to regulate the immune system to provide a targeted, neutralizing antibody response without generating off-target, non-neutralizing antibodies that can lead to antibody dependent enhancement of disease (ADE); further a complete vaccine should activate the appropriate T cell responses to yield long-term immune memory without activating detrimental Th2 responses that have been associated with immune-related complications of COVID-19 disease.
Generex also announced that significant progress has been made on the li-Key-SARS-CoV-2 vaccine program. The team at NGIO has completed the T Cell assays and HLA typing of blood samples from 46 convalescent COVID-19 patients and 30 healthy pre-COVID donors (from 2017 and 2018), screening the immune regulatory activity of 33 Ii-Key epitopes. The results of the T cell screen demonstrated that numerous Ii-Key epitopes activate CD4+ Th1 and CD8+ responses; none of the Ii-Key epitopes tested activated any negative Th2 responses.
Additionally, the Ii-Key epitopes have been used to bind and purify IgG antibodies from convalescent COVID-19 patient samples. These antibodies are being tested against live SARS-CoV-2 virus in a level 3 biocontainment laboratory to ensure that they neutralize the virus. Once confirmed as neutralizing, these Ii-Key epitope binding antibodies can be purified and genetically engineered to develop antibody therapeutics against COVID-19.
Based on the results of the ex-vivo human studies, Generex has initiated GMP production of several Ii-Key-SARS-CoV-2 epitopes that will be formulated for Phase I and Phase II clinical trials; an IND is being prepared for FDA submission in early 2021. With multiple epitopes that are targeted to generate specific, neutralizing regions of the coronavirus without off-target effects, and which have demonstrated positive T cell regulation necessary for long-term immune memory, the Ii-Key COVID-19 vaccine has the potential to be a complete vaccine.
It has been widely reported that the SARS-CoV-2 virus, like all viruses, is mutating. Some of the mutational variants, with mutations that mainly occur in the virus spike protein, appear to have biological differences that may alter infectivity, transmission, and severity of infection. The Ii-Key vaccine platform is built to address issues of mutation. First, there are multiple Ii-Key-SARS-CoV-2 peptides, each containing multiple epitopes in the vaccine formulation. So even if there is one mutation, the other epitopes should provide protection. Second, if a new strain emerges, the Ii-Key platform can be rapidly deployed to make the new, mutant sequence with Ii-Key and add it to the current vaccine. This is the beauty of the Ii-Key technology. Further, the epitopes predicted by computational algorithms exclude regions of the coronavirus that are susceptible to mutation, so the Ii-Key vaccine largely eliminates mutagenic regions from the start.
With an impending IND submission for Phase I and II human clinical trials to evaluate safety and immunogenicity of the Ii-Key vaccine, NGIO is exploring additional opportunities to deploy the targeted Ii-Key COVID-19 vaccine as a universal booster for RNA, DNA, and inactivated virus vaccines that contain the entire spike protein and have the potential to elicit off-target and over-active immune responses. Recent reports of immune related side effects after booster inoculation with RNA vaccines include fever, chills, fatigue, and joint pain. These immune related side effects to the RNA vaccine mimic the immune response to coronavirus infection to provide immunity to COVID-19 as evidenced by 90+% efficacy rate. However, these strong immune responses also have the potential to lead to ADE, as has been shown in SARS-1, and questions remain as to the ability of the RNA vaccines to generate long-term immune memory. The targeted Ii-Key-SARS-CoV-2 vaccine is designed to generate long-term immune memory through specific T cell activation by the Ii-Key, and the antibody purification studies demonstrate the potential for the Ii-Key vaccine to elicit a targeted, neutralizing immune response without off-target effects. Using a targeted Ii-Key-SARS-CoV-2 vaccine as a universal booster may provide long-term immunity without causing the immune related side effects from off-target responses. Such a universal Ii-Key vaccine booster could significantly extend the currently limited supply of RNA vaccines, and with a clean side effect profile the Ii-Key booster may increase consumer acceptance.
Generex CEO, Joseph Moscato said, “Throughout this challenging year of 2020, we have overcome numerous hurdles to reach this point with our Ii-Key COVID-19 vaccine. We have filed an extensive patent application that covers our Ii-Key-SARS-CoV-2 vaccine and provides the foundation for a new patent estate for the Ii-Key platform. The results of our ex vivo human studies have been better than expected, and we have several Ii-Key epitopes that regulate the immune responses we seek in a vaccine formulation. The antibody data are especially encouraging. The results confirm that we are targeting immunologically important regions of the virus and demonstrate the ability to purify neutralizing antibodies from patient serum that can be developed as a targeted antibody therapeutic against COVID-19.
“The Ii-Key vaccine is designed to be a Complete Vaccine, and we believe that our technology offers the safest and best route for the rapid development of a COVID-19 vaccine that can be safely administered to everyone, including adolescents, children and pregnant women without worry of immune related side effects. As we prepare for our first in human studies of the vaccine in healthy adults, we also plan to include underserved populations with risk factors for COVID-19, elderly subjects who are at high risk for serious complications from coronavirus infection, and working with our SAB, we are planning a focused clinical program for adolescents, children, and pregnant women.”
Mr. Moscato continued, “On the international front, we are moving forward with our partners in Malaysia and China on the development of the Ii-Key-SARS-CoV-2 vaccine. Bintai Kinden is supporting our US development efforts in exchange for exclusive distribution rights in Malaysia and Southeast Asia. We have also initiated discussions with our Chinese partners on the technology transfer, GMP production, and regulatory filings with the NMPA for the Phase I, II and III clinical programs in China. This partnership in China will also enable us to explore the potential of the Ii-Key-SARS-CoV-2 vaccine as a universal booster.
“We look forward to an exciting 2021 as we advance the Ii-Key COVID vaccine into the clinic with the goal of gaining FDA approval for a Complete Vaccine™. On behalf of the Generex and NGIO management teams, we wish our shareholders and investors a happy, healthy, and prosperous New Year as we continue to execute our plans to build value for the future.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
Looks like it!! Excited!
Why news today! I was hopinf for next week. But hey ill take it!
Niiiccceee!
Looking steady could see a pop soon. Shares excuted
Good to see filings. GNBT should make a nice move up soon. This is taking a long time but patience pays.
Nice volume today!
That is correct. Theres 22 million pending after. Major money
I agree docj. Not only that with 2 dollars in royalties from each dose. It will bring a massive amount of money to GNBT and lets not forget The IPO going live, whenever that may be lol. However I see a lot of money in GNBTs near future
GNBT - 8K released - On December 15, 2020, Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) agreed and signed an extension for the receipt of the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment from the “Joint Entity” (the “Extension Agreement”) as set forth under the Ii-Key Innovative Vaccine Development Agreement signed November 13, 2020 (the “Agreement”), with Beijing Youfeng International Consulting Co., Ltd (“BYIC”), National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control
Lol I know. Ive been trading for a long time. Patience is the main key
News should be dropping soon. Its been a few weeks without updates
Hoping to hear some news by next week. Biotech sector is super hot. PGE and MRNA are killing it right now
There is a possibility. It depends on which healtcare companies are involved.
Generex CEO, Joseph Moscato said, “Our partners in China understand the science and the power of the Ii-Key technology for the regulation of the immune system to develop safe and effective vaccines for infectious disease and cancer, and with this agreement, we cement our partnership to realize the full potential of our Ii-Key vaccine technology. With this partnership, Generex is perfectly positioned in China to deploy the Ii-Key platform as the leading technology for rapid response to emerging infectious diseases. We look forward to working in mutual collaboration with our partners to advance the Ii-Key vaccine development platform.”
Mr. Moscato continued, “This is probably the biggest deal Generex could even imagine and we are all too happy to be partners with these acclaimed institutions to help China and the world alleviate the threat of pandemic infections. Plus, we now have the ability to advance our Ii-Key cancer platform to realize the full potential of Ii-Key immunotherapies to target tumor biomarkers across oncology indications. The Ii-Key-SARS-CoV-2 vaccine is the first product under this Ii-Key platform license, and in the coming days, we will announce agreements for additional Ii-Key vaccine development projects as well as licensing deals for other products from the NuGenerex family of companies.”
Amazing News! Lets see dollar land!